Can you take Cervarix with Fruquintinib?

Fruquintinib has a moderate potential interaction with Bleeding Associated with Coagulation Defect.

Fruquintinib increases the risk of hemorrhagic events which may lead to fatal outcomes. Closely monitor patients who are at risk for bleeding.

Fruquintinib has a moderate potential interaction with Bleeding Disorder.

Fruquintinib increases the risk of hemorrhagic events which may lead to fatal outcomes. Closely monitor patients who are at risk for bleeding.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Dehydration.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a major potential interaction with Fever.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

Fruquintinib has a moderate potential interaction with High Blood Pressure.

Hypertension was reported in patients taking fruquintinib. Fruquintinib should not be initiated in patients unless blood pressure is adequately controlled.

Fruquintinib has a moderate potential interaction with History, Thrombotic/Thromboembolic Disorder.

Fruquintinib may increase the risks for arterial thromboembolic events. Initiation of fruquintinib in patients with a recent history of thromboembolic events should be carefully considered.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Hypotension.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Immunodeficiency.

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

The human papillomavirus vaccine in Cervarix has a major potential interaction with Infection.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

Fruquintinib has a moderate potential interaction with Infection.

Infection was reported in patients taking fruquintinib. Fruquintinib should not be initiated in patients with active infections. Closely monitor for infection during treatment and withhold treatment during active infection.

Fruquintinib has a moderate potential interaction with Liver Disease.

Fruquintinib has not been evaluated in patients with moderate hepatic impairment (total bilirubin greater than 1.5 times and less than 3 times ULN and any AST) and it is not recommended for treatment in patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST).

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Syncope.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.